Maximus (NYSE:MMS – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 5.700-6.000 for the period, compared to the consensus earnings per share estimate of 5.070. The company issued revenue guidance of $5.3 billion-$5.4 billion, compared to the consensus revenue estimate of $5.3 billion. Maximus also updated its FY25 guidance to $5.70-6.00 EPS.
Maximus Stock Up 0.9 %
NYSE MMS traded up $0.72 during mid-day trading on Wednesday, reaching $80.53. 1,456,258 shares of the company’s stock traded hands, compared to its average volume of 377,697. The company has a market cap of $4.85 billion, a price-to-earnings ratio of 16.73 and a beta of 0.77. Maximus has a 1-year low of $76.46 and a 1-year high of $93.97. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.61. The company has a fifty day simple moving average of $88.75 and a 200-day simple moving average of $88.18.
Maximus Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Saturday, November 30th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 1.49%. Maximus’s dividend payout ratio is 25.16%.
Insiders Place Their Bets
About Maximus
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
See Also
- Five stocks we like better than Maximus
- Investing In Preferred Stock vs. Common Stock
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- 3 REITs to Buy and Hold for the Long Term
- Williams-Sonoma Stock: Buy It and Never Let It Go
- 3 Small Caps With Big Return Potential
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.